

1 **Autophagy-associated Production of Antimicrobial Peptides hBD1 and LL37**

2 **Exhibits Anti-Bacillus Calmette-Guérin Effects in Lung Epithelial Cells.**

3

4 Rui-ning Wang^{#a}, Hong-lin Liu^{#a}, Yao-xin Chen^{#a}, Qian Wen^{#a}, Xin-ying Zhou^{#a},

5 Jin-li Wang^{#a}, Jia-hui Yang^{#a}, Yan-fen Li^{#a}, Zhen-yu Han^{#a}, and Li Ma^{*,#a}

6

7 ^{#a}Institute of Molecular Immunology, School of Laboratory Medicine and

8 Biotechnology, Southern Medical University, Guangzhou 510515, China

9

10 ***Corresponding author**

11 Li Ma, Institute of Molecular Immunology, School of Laboratory Medicine and

12 Biotechnology, Southern Medical University, Guangzhou 510515, China. Tel:

13 +86-20-61648322, Fax: +86-20-61648322, E-mail: maryhmz@126.com

14

15

16 **Abstract**

17 Antimicrobial peptides (AMPs) constitute important groups of bactericidal
18 polypeptides against various microorganisms that exhibit their anti-bacteria activity
19 through cleavage of precursor peptides into the active form of 50–100 amino acids in
20 length. Various AMP cleavage mechanisms have been reported in different cell types;
21 however, those in *Mycobacterium tuberculosis* (MTB)-infected lung epithelial cells
22 remain unknown. In the present study, we found that MTB-infected lung epithelial
23 cells expressed high level of the AMPs hBD1 and LL37 to kill intracellular MTB as
24 the first-line immune barrier against MTB infection. Notably, their production in the
25 lung epithelial cells was closely related to the function of autophagosomes and
26 lysosomes. Experimental induction of autophagy in lung epithelial cells could
27 enhance the expression of active hBD1 and LL37 at the post-transcriptional level,
28 whereas silencing of these two active AMPs could decrease the bactericidal effect of
29 autophagy. These findings indicated that cleavage of peptide precursors to form active
30 AMPs might constitute a previously unrecognized antibacterial mechanism of
31 autophagy.

32

33 **Author summary**

34 LM and RW conceived and designed the experiments; RW performed the
35 experiments and analyzed the data; QW analyzed the data and contributed
36 reagents/materials/analysis tools; HL performed the experiments; XZ, JY, YL and ZH
37 analyzed the data. LM and RW drafted the manuscript.

38 **Introduction**

39 Tuberculosis (TB), the second leading cause of fatal infectious disease, results
40 from *Mycobacterium tuberculosis* (MTB) infection that mainly affects the lung. Until
41 2019, over 10.0 million people have been infected by MTB among whom 186,772
42 carried rifampicin-resistant MTB/multidrug-resistant [1]. As a barrier against
43 infection, the alveolar epithelium constitutes an essential component of innate and
44 mucosal immunity in the lung. Composed of type I and II pneumocytes, it can detect
45 pathogens via pattern recognition receptors and secrete surfactant proteins, cytokines,
46 chemotactic factors, and antimicrobial peptides (AMPs). MTB can invade alveolar
47 epithelial cells and proliferate therein [2–4], eventually leading to host cell necrosis,
48 tissue damage, and epithelial barrier damage [5]. However, although AMPs are
49 known to play distinct roles in the barrier function against MTB invasion, they are
50 relatively poorly characterized compared with other effector molecules.

51 AMPs comprise a group of polypeptides consisting of 50–100 amino acids that
52 exist in many tissues and cell types, exhibit antimicrobial activity against a variety of
53 microbes, such as bacteria, fungi, and some viruses including MTB [6], and can be
54 divided into three families: defensins, cathelicidins, and histatins. Defensins can be
55 further divided into α -, β -, and θ -defensins. α -defensins, primarily detected in
56 neutrophils, are also termed human neutrophil peptides. β -defensins, mainly
57 expressed in epithelial cells [7,8], exhibit wide taxonomic distribution [9,10].
58 Notably, MTB infection can stimulate human corneal fibroblasts [11], human
59 endothelial cells [12], and human airway epithelia [13,14] to secrete β -defensin 1

60 (hBD1). Cathelicidins exhibit distinct structure and evolution from defensins albeit
61 similar wide distribution and abundance [15]. LL37, the only type of human
62 cathelicidin identified to date, is mainly expressed in neutrophils and respiratory
63 epithelial cells. LL37 has important roles in various types of infectious disease and
64 lung immune responses [16] including anti-TB function and can inhibit intracellular
65 MTB growth [17].

66 Owing to the indispensable role of AMPs in the first-line defense barrier to MTB
67 invasion, their expression mechanism has received considerable attention. AMPs are
68 generally expressed as precursors and cleaved by various proteases to release the
69 active peptides [18], with different mechanisms depending on the cell and AMP type.
70 The human cathelicidin gene (*CAMP*) encodes an 18 kDa inactive precursor protein
71 (hCAP18). In human neutrophils, the hCAP18 C-terminus is released by proteolytic
72 hydrolysis, forming an active antimicrobial peptide consisting of 37 amino acids,
73 termed LL37 [19]. hCAP18 can also be cleaved by elastase from azurophilic granules
74 during the exocytosis and phagocytosis process in neutrophils [20]. Defensins also
75 exhibit similar shear mechanism. α -defensins are generally synthesized in neutrophils
76 and stored as the active peptides in granules after being processed from their
77 precursors to the mature form [21–23]. Nevertheless, AMP processing mechanisms
78 are also vary depending on microbial structures and inflammatory mediators [24,25]
79 and remain incompletely understood.

80 Notably, it has been reported that autophagy contributes to AMP cleavage and
81 anti-MTB activity. Generally, autophagy is identified as a physiological process of

82 cells to maintain self-homeostasis by degrading intracellular contents through
83 acidification and hydrolase via lysosome fusion [26]. Based on this degradation
84 process, we hypothesized that autophagy also plays a role in cutting proteins.
85 Consistent with this, autophagosomes can selectively encapsulate innocuous
86 cytoplasmic components via autophagic adapter protein p62 and process them into
87 short peptides with anti-MTB antimicrobial activity [27]. Moreover, autophagy can
88 also exert anti-MTB activity through multiple mechanisms; in turn, MTB infection
89 can induce autophagy in various cells. For example, macroautophagy participates in
90 MTB clearance in mouse and human macrophage cell lines [26,28]. It is generally
91 believed that autophagy can encapsulate MTB-containing phagosomes for lysosome
92 fusion, wherein the wrapped MTB is degraded by proteolytic enzymes [29].
93 Furthermore, the ribosomal protein rps30 can be degraded by autophagy via p62 to
94 produce short peptides, which act in concert with lysosomal hydrolases to kill MTB in
95 autophagosomes [27].

96 Therefore, in this study we examined whether other novel AMPs might be
97 produced by autophagic degradation and whether autophagy could cleave AMP
98 precursors to active peptides as a new mechanism of autophagic anti-MTB
99 functionality. We used A549 and BEAS-2B cells as epithelial cell models to screen
100 for highly expressed AMPs following MTB infection, identifying AMPs hBD1 and
101 LL37 and examining their roles in defense against MTB invasion in lung epithelial
102 cells. To further explore the mechanism, we correlated the active peptide levels of
103 hBD1 and LL37 with autophagy and autolysosome formation and verified the

104 importance of AMPs in autophagy-mediated MTB lethality. Expounding these
105 mechanisms will help to further understand the role of lung epithelial cells as the
106 first-line barrier against MTB infection and the previously unrecognized mechanism
107 of autophagy against intracellular MTB. Such knowledge may have considerable
108 significance for augmenting anti-TB immune mechanisms and developing new TB
109 treatment strategies.

110

111 **Materials and methods**

112 ***Patients and specimens***

113 For the use of clinical materials for research purposes, prior approval was
114 obtained from the Southern Medical University Institutional Board (Guangzhou,
115 China). All tissue samples were collected and analyzed in a manner consistent with
116 the prior written informed consent of the patients and healthy tissue donors. A total of
117 three patients with lung TB were examined for lung pathology; TB was confirmed
118 through positive acid-fast staining. Patient tissue was obtained during the puncture
119 examination. Healthy tissue was obtained from a total of two volunteers as normal
120 tissue adjacent to resected tumors. And the peripheral blood mononuclear cells
121 (PBMCs) samples were collected and analyzed in a manner consistent with the prior
122 written informed consent of the patients and healthy donors.

123

124 ***Antibodies and reagents***

125 The following reagents were used in this study: 3-methyladenine (3-MA;

126 M9281; Sigma-Aldrich, St. Louis, MO, USA), dimethylsulfoxide (D2650;
127 Sigma-Aldrich), baflomycin A1 (Baf A1; sc-201550; Santa Cruz, Dallas, TX, USA),
128 TRIzol reagent (15596-018; Invitrogen, Carlsbad, CA, USA), rapamycin (V900930;
129 Sigma-Aldrich), and NH₄Cl (A9434; Sigma-Aldrich). The following antibodies were
130 used in this study: anti-GAPDH (TA-08; ZSGB-BIO, Peking, China), anti-ATG 5
131 (12994; Cell Signaling Technology, Danvers, MA, USA), anti-ATG 7 (8558; Cell
132 Signaling Technology), anti-p62 (23214S; Cell Signaling Technology), hBD1
133 (ab170962; Abcam, London, UK), hCAP18 (ab80895; Abcam), and LL37 (ab69484;
134 Abcam). The used antibody dilutions is 5% Bovine serum albumin dissolved in Tris
135 Buffered Saline with Tween® 20 (TBST-10X) (A1933; Sigma-Aldrich).

136

137 ***Bacterial and cell culture***

138 *M. bovis* Bacillus Calmette-Guérin (BCG) strain 19015 was purchased from the
139 American Type Culture Collection (ATCC, Manassas, VA, USA). BCG were grown
140 in Middlebrook 7H9 broth medium (271310; Sparks, MD, USA) or on 7H10 agar
141 medium (26271; Sparks) supplemented with BBL Middlebrook oleic
142 acid-albumin-dextrose-catalase (OADC) in an incubator (37 °C, 5% CO₂). Human
143 monocyte-derived macrophages (HMDMs) was isolated from healthy donors' blood
144 and were cultured in Roswell Park Memorial Institute (RPMI) 1640 Medium
145 supplemented with 10% fetal bovine serum (35-076-CV; Coring, New York, USA)
146 and 20 ng/µL Recombinant Human GM-CSF (300-03; Peprotech, Rocky Hill,
147 USA). BEAS-2B cells (CRL-9609; ATCC) were cultured in Bronchial Epithelial Cell

148 Growth Medium (CM2010; CellCook, Guangzhou, China). THP1 cells (TIB-202;
149 ATCC) were cultured in RPMI 1640 Medium supplemented with 10% fetal bovine
150 serum (35-076-CV; Corning). A549 cells (CCL-185; ATCC) were cultured in
151 Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum.
152 A549 cells were infected with GFP-LC3 lentivirus (17-10193; Millipore, Bedford,
153 MA, USA) according to manufacturer instruction. After three weeks, stable
154 transfectants expressing GFP were selected using fluorescence-activated cell sorting
155 (BD Biosciences, San Jose, CA, USA). LC3 overexpression in the transfectants was
156 confirmed by western blotting, and the formation of LC3 puncta in infected cells
157 following stimulation with rapamycin was observed using fluorescence microscopy.

158

159 ***siRNA and transient transfection***

160 siRNAs were purchased from RiboBio (Guangzhou, China). A549 and
161 BEAS-2B cells (at approximately 50% confluence) were transiently transfected with
162 40 pM si-control and siRNAs for other genes using Lipofectamine 2000 (Invitrogen)
163 according to manufacturer instruction. siRNA sequences are listed in Table 1.

164 **Table 1. Sequence of siRNAs used in this study**

Gene	Sequence (5'-3')
<i>DEFB1 (hBD1)</i>	1: GCCACAGATCTGATCATTA 2: CGATCTTACCAAAATTCA
<i>LL37 (CAMP)</i>	1: TCCGGAAATCTAAAGAGAA 2: GTCCAGAGAATCAAGGATT

	3: CAAGGAAGCTGTGCTTCGT
<i>p62 (SQSTM1)</i>	1: GGAGGATCCGAGTGTGAAT
	2: GGAGTCGGATAACTGTTCA
	3: TACAAATTAACAGGATGG
<i>ATG5</i>	1: GGUUUGGACGAAUUCACUUGUUU
	2: GAUCACAAGCAACUCUGGAUGGGAU
	3: GCCAUCAAUCGGAAACUCAUGGAAU
<i>ATG7</i>	1: CAGCATCATCTTCGAAGTGAA
	2: CAAGAGAAAGCTGGTCATCAA
	3: ATCAGTGGATCTAAATCTCAA

165

166 ***Western blotting***

167 Whole cell extracts were prepared in the presence of protease inhibitor cocktail
168 (Roche, Mannheim, Germany), phosSTOP phosphatase inhibitor cocktail (Roche),
169 and 1 mM dithiothreitol (Biosharp, Shanghai, China). The cell extracts were resolved
170 using sodium dodecyl sulfate-polyacrylamide gel electrophoresis, transferred to
171 polyvinylidene fluoride membranes (Merck kGaA, Darmstadt, Germany), blocked
172 using 5% bovine serum albumin for 1 h and incubated with diluted primary antibodies
173 at 4 °C overnight. Western blots were developed using horseradish
174 peroxidase-conjugated secondary antibodies, followed by detection with enhanced
175 chemiluminescence. The results were analyzed using Adobe Photoshop CC 2017
176 (Adobe Systems Incorporated, San Jose, CA, USA); all the resultant bands were in the

177 linear range (0–255 pixels).

178

179 ***Confocal microscopy***

180 A549 cells were grown on glass coverslips and treated with different stimulants,
181 followed by fixation, permeabilization, and blocking. The coverslips were incubated
182 with primary antibody at 4 °C overnight, then with secondary antibody for 1 h at
183 room temperature. Nuclei were labeled with 4,6-diamidino-2-phenylindole staining.
184 Before fixation, LysoTracker™ Blue DND-22 (Invitrogen, L7525) staining was
185 performed by adding Lyso tracker (70 µM) to cells and incubating at 37 °C for 30
186 min. Coverslips were mounted with ProLong Gold antifade reagent (Invitrogen) and
187 visualized using 60× mirror confocal microscopy (Zeiss, Göttingen, Germany).

188

189 ***RNA isolation and quantitative real-time reverse transcription-polymerase chain***
190 ***reaction (qRT-PCR)***

191 Total RNA was isolated using TRIzol reagent according to manufacturer
192 recommendation. cDNA was synthesized using TransScript One-Step gDNA
193 Removal and cDNA Synthesis SuperMix (AT311-03; TransGen Biotech, Guangzhou,
194 China). For real-time qPCR analysis (40 cycles), TransStart Top Green qPCR
195 SuperMix and an Eppendorf Mastercycler were used. *GAPDH* was used as
196 housekeeping gene for data normalization. The primer sequences were: hBD1, 5'-
197 TGAGATGGCCTCAGGTGGT -3' (forward) and 5'-
198 GCAGGCAGAATAGAGACATTGC -3' (reverse); LL37, 5'-

199 GTCCTCGGATGCTAA CCT CT-3' (forward) and 5'-TCT GGT GAC TGC TGT
200 GTC G-3' (reverse); and *GAPDH*, 5'-GTC TCC TCT GAC TTC AAC AGC G-3'
201 (forward) and 5'-ACC ACC CTG TTG CTG TAG CCA A-3' (reverse).

202

203 ***Colony-forming units (CFU) assay***

204 A549 and BEAS-2B cells were infected with BCG at a multiplicity-of-infection
205 (MOI) of 5. After 1 h incubation at 37 °C, the infected cells were washed extensively
206 with phosphate-buffered saline to remove extracellular mycobacteria, lysed using 1
207 mL of 0.01% Triton X-100 in distilled water, and 10-fold serially diluted to perform
208 quantitative culture. The aliquots of each dilution were inoculated in triplicate on
209 Middlebrook 7H10 agar plates supplemented with OADC. After 3-week incubation,
210 the number of colonies was counted to determine the amount of intracellular viable
211 bacilli. The survival rate of BCG at 72 h was calculated compared with that at 0 h.

212

213 ***Co-immunoprecipitation (Co-IP)***

214 Protein lysates used for Co-IP were prepared from A549 cells. Cells were
215 harvested, lysed in IP buffer containing 0.3% CHAPS Detergent (10810118001;
216 Roche), 40 mM HEPES (pH 7.5), 120 mM NaCl, 1 mM EDTA-2Na, and protease
217 inhibitor cocktail (5892791001; Roche), then centrifuged at 12,000 × g (4 °C, 15 min).
218 The supernatant was collected and incubated with p62 primary antibodies and protein
219 G-agarose beads overnight at 4 °C. The beads were washed five times with IP buffer
220 before processing for western blotting analysis.

221

222 ***Immunohistochemistry***

223 Immunohistochemistry staining was performed using a Dako Envision System
224 (Carpinteria, CA, USA) following the manufacturer's recommended protocol. Briefly,
225 4 μ m thick tissue sections were incubated with anti-LL37 antibody at 4 °C overnight.
226 Nuclear staining was regarded as a positive signal. Then, the tissue sections were
227 incubated with biotinylated secondary antibody (Zymed, San Francisco, CA, USA),
228 further treated with streptavidin-horseradish peroxidase complex (Zymed), immersed
229 in 3-amino-9-ethyl carbazole, counterstained with 10% Mayer's hematoxylin,
230 dehydrated, mounted in Crystal Mount, and finally paraffin embedded. The tissue
231 sections were scored by two independent observers.

232

233 ***Electron microscopic analysis***

234 A549 and BEAS-2B cells in T25 flasks were infected with BCG for 1 h with a
235 MOI of 5. At that time, the cells were fixed in 1% glutaraldehyde and processed for
236 conventional transmission electron microscopy. Micrographs were taken from each
237 sample, and the percentage of bacteria-containing cells were counted. For Electron
238 microscopic analyzing, we thank the Central laboratory Southern Medical University,
239 for technological assistance.

240

241 ***Mass spectrometric analysis***

242 To confirm the western blotting bands of AMPs, Mass spectrometric analysis

243 was performed. A549 cells were infected with BCG for 48 h at a MOI of 5, samples
244 were separated on 12% SDS-PAGE. The gel bands corresponding to the targeted
245 protein were excised from the gel, reduced with 10 mM of DTT and alkylated with 55
246 mM iodoacetamide (I1149; Sigma-Aldrich). Then the gel was digested with trypsin
247 (T1763; Sigma-Aldrich) at 37 °C for 6 h. Vortexing the gel for 5 min in 100%
248 acetonitrile for 5 min and in 0.1% benzoic acid aqueous solution for 5 min, then in
249 100% acetonitrile for 5 min. The extractions were then centrifuged at 10,000 x g for
250 15 min. Then the sample were analyzed in Thermo Scientific™ Orbitrap Fusion™
251 Tribrid™, a liquid chromatography–mass spectrometry (LC–MS) system. And the
252 data were analyzed by Proteome Discoverer software (1.2 version, Thermo Fisher
253 Scientific, Waltham, MA, USA). For mass spectrometry analyzing, we thank the
254 Central laboratory Southern Medical University, for technological assistance.

255

256 ***Statistical analysis***

257 All the measurement data are presented as the means ± standard deviation.
258 Real-time PCR data were analyzed using one-way analysis of variance and least
259 significant difference multiple comparison tests. Data between two groups were
260 compared using the Student's *t*-test. P-values were two-sided and a P-value < 0.05
261 indicated the presence of a statistically significant difference.

262

263 **Results**

264 ***Antimicrobial peptides hBD1 and LL37 are highly expressed in MTB-infected lung***

265 *epithelial cells and exhibit anti-MTB activity*

266 To determine whether AMPs play important roles in MTB infection in lung epithelial
267 cells, we infected A549 and BEAS-2B cells with BCG and measured the mRNA
268 levels of various AMPs. To confirm BCG infection, we performed electron
269 microscopy (EM) analysis of BCG-infected A549 and BEAS-2B cells (S1 Fig). EM
270 images showed that BCG (red arrow) were engulfed by A549 and BEAS-2B cells and
271 enveloped by bilayer membrane autophagosomes (yellow arrow). However, as BCG
272 enveloped by autophagosomes were destroyed, it was difficult to visualize the
273 complete bacterial structure. This result illustrates that the mRNA levels of defensin
274 hBD1 and cathelicidin LL37 were obviously higher than those of other AMPs in
275 BCG-infected A549 cells (Fig 1A). Therefore, A549 cells were infected with BCG
276 and LL37 and active hBD1 production was detected by qPCR or western blotting.
277 BCG could effectively stimulate LL37 and hBD1 production at both mRNA and
278 protein levels in A549 cells (Fig 1B, 1C&1D). To confirm these results, we detected
279 LL37 and hBD1 expression in primary epithelial BEAS-2B cells, obtaining similar
280 results (S2A, S2B&S2C Fig). Moreover, we found that hBD1 and LL37 mRNA levels
281 were higher in peripheral blood mononuclear cells (PBMCs) from patients with MTB
282 compared with healthy donors, indicating that these two AMPs might be involved in
283 the process of MTB infection (Fig 1E&1F). To further confirm this result, we tested
284 the level of LL37 by immunohistochemistry in lung biopsies of patients with MTB,
285 revealing that their alveolar type II epithelial cells (but not immune cells) could
286 produce much higher levels of LL37 than those in normal lung tissue sections and

287 from patients with pneumoconiosis (Fig 1G). Similar results were obtained based on
288 morphological features and hematoxylin staining (S3A&S3B Fig). This result was
289 consistent with reports that AMPs are mainly expressed by epithelial cells [7, 8].
290 Additionally, we detected *hBD1* and *LL37* mRNA levels in THP1 and HMDM cells
291 compared to those in lung epithelial cells, revealing that both AMPs exhibited higher
292 expression in lung epithelial cells, consistent with the immunohistochemistry results
293 (S4 Fig) and further verifying that the choice of alveolar type II epithelial cells as the
294 model in our study is reasonable because these cells are capable of producing high
295 levels of AMPs [7,8].

296 To confirm whether these two AMPs participated in the anti-MTB process in A549
297 and BEAS-2B cells, we performed CFU assays. A549 and BEAS-2B cells transiently
298 transfected with si-control or si-DEFB1 or/and si-CAMP were infected with BCG.
299 hBD1 or/and LL37 depletion significantly increased intracellular BCG survival in
300 A549 (Fig 1I, 1J&1K) and BEAS-2B cells (S2G, S2H&S2I Fig). These results
301 suggested that LL37 or/and hBD1 depletion impaired intracellular MTB elimination
302 from lung epithelial cells, with these AMPs potentially functioning as effector
303 molecules during the anti-MTB process in A549 and BEAS-2B cells.

304

305 ***Autophagy influences hBD1 and LL37 active peptide levels***

306 The autophagy-targeting molecule p62 (A170 or SQSTM1) is involved in killing
307 MTB by specifically delivering ribosomal and bulk ubiquitinated cytosolic proteins to
308 autolysosomes to produce AMPs [30]. Accordingly, we hypothesized that the

309 autophagic level of cells might affect AMP production. To confirm our hypothesis,
310 we used rapamycin, an autophagy agonist, to induce autophagy in A549 and
311 BEAS-2B cells and measured hBD1 and LL37 production. BCG infection and
312 rapamycin treatment increased autophagy level in A549 cells (Fig 2A). Rapamycin
313 could effectively stimulate the production of active peptides of both AMPs, whereas
314 the mRNA levels did not differ between rapamycin-treated and control groups (Fig
315 2A&2B). Similar results were obtained in BEAS-2B cells (S2 Fig). Furthermore,
316 alternative autophagy stimulation in A549 cells via starvation culture medium with
317 Earle's balanced salt solution (EBSS) also increased AMP protein but not mRNA
318 levels (Fig 2C&2D). Application of 3-MA to disturb the autophagic process in A549
319 and BEAS-2B cells decreased the active peptides of both AMPs whereas the mRNA
320 levels remained unchanged (Fig 2A&2B and S2D, S2E&S2F Fig). Moreover, we used
321 siRNA to silence autophagy-related protein 5 and 7 (ATG 5 and ATG 7) to generate
322 autophagy-defective A549 cells. Notably, BCG could not stimulate active LL37 and
323 hBD1 production in ATG 5- and ATG 7-deficient cells, despite increased mRNA
324 levels (Fig 2E&2F). To further study the relationship between AMPs production and
325 autophagy, we overexpressed hBD1 and LL37 precursor-mCherry and LC3-GFP in
326 A549 cells. Upon BCG or rapamycin stimulation, hBD1 and LL37 precursor
327 co-localization with LC3 puncta could be observed (Fig 3&4), supporting that AMP
328 precursor was recruited into the autophagosomes. Conversely, under 3-MA treatment,
329 hBD1/LL37 precursor and LC3 puncta co-localization was decreased (Fig 2G). These
330 results showed that the autophagic level of lung epithelial cells affected hBD1 and

331 LL37 active peptide but not mRNA levels and that AMP precursors entered
332 autophagosomes, indicating that in the process of AMP production, autophagy plays
333 an indispensable role at the post-transcriptional level.

334

335 ***hBD1 and LL37 production are affected by lysosome function***

336 To ensure complete sequestration during autophagy, the macromolecules and
337 organelles should be delivered from autophagosomes to lysosomes, finally forming an
338 autolysosome [31]. Thus, we hypothesized that the precursors of hBD1 and LL37
339 might be captured by autophagosomes and delivered to lysosomes to be cut into
340 AMPs and exhibit their anti-MTB activity. We used Baf A1, an inhibitor of
341 autophagosome formation that can block the fusion between autophagosomes and
342 lysosomes, to treat BCG-infected A549 cells and measured the production of hBD1
343 and LL37 active peptides and mRNA. Baf A1 could effectively reduce active hBD1
344 and LL37 production (Fig 4A) whereas it did not affect their mRNA levels (Fig 4B).
345 We next applied NH₄Cl to disturb lysosomal and autophagosomal function, which
346 obviously reduced active AMPs production (Fig 4C) but did not affect their mRNA
347 levels (Fig 4D).

348 Furthermore, immunofluorescence to reflect the co-location of hBD1/LL37
349 precursor with autophagosomes and lysosomes showed that in A549 cells, the
350 precursors of hCAP18 exhibited colocalization with autophagosomes and lysosomes,
351 suggesting that the AMP precursors entered in autophagosomes (Fig 6&7). However,
352 BCG infection of A549 cells treated with Baf A1 or NH₄Cl did not alter the

353 colocalization among hCAP18, autophagosomes, and lysosomes, even upon
354 rapamycin stimulation (Fig 5E&5F). This indicated that autolysosome formation and
355 function were not involved in AMP precursor recruitment. Thus, whereas the fusion
356 of autophagosomes with lysosomes and lysosomal function are vital for active AMP
357 production, these exert no effect on AMP precursor recruitment.

358

359 ***Autophagy adapter protein p62 controls active AMP production by interacting with***
360 ***AMP precursors***

361 p62/SQSTM1 is a kind of scaffold protein exhibiting multiple biological functions
362 such as being a selective autophagy receptor for degradation by sensing ubiquitinated
363 cargos [30]. We hypothesized that AMP precursors might be recruited into
364 autophagosomes by selectively interacting with p62. To investigate whether p62
365 could influence AMP production, A549 cells transiently transfected with si-control or
366 si-SQSTM1 were infected with BCG. Our analysis showed that endogenous p62
367 expression was effectively inhibited by the siRNA and that p62 depletion significantly
368 reduced active hBD1 and LL37 but not mRNA production at indicated time points
369 (Fig 8A&8B).

370 Additionally, p62, hBD1/LL37 precursor, and LC3 puncta co-localization was
371 observed under BCG stimulation in A549 cells. The results revealed co-localization
372 between p62 and hBD1/LL37 precursor in the cytoplasm and autophagosomes and
373 indicated that the co-localization rates between hBD1/LL37 precursor and
374 p62-positive autophagosomes were influenced by the autophagy level of A549 cells

375 (Fig 8C, Fig 9&10). Furthermore, we performed Co-IP to directly measure and further
376 confirm the interaction of p62 with AMP precursors. Under BCG stimulation, p62
377 interacted with hCAP18 (Fig 8D), suggesting that p62 is required for the autophagic
378 production of active AMPs.

379

380 ***Autophagy-related AMP production is a novel mechanism of autophagy-mediated***
381 ***MTB killing***

382 To verify whether the post-transcriptional promotion of active AMP production by
383 autophagy can play a role in killing intracellular MTB, a CFU assay was performed.
384 Firstly, A549 and BEAS-2B cells were transiently transfected with si-control,
385 si-DEFB1, or si-CAMP to silence hBD1 or/and LL37 and infected with BCG. Then,
386 autophagy was further induced by rapamycin, and cells were lysed after 72 h. The
387 results of CFU showed that under the induction of autophagy by rapamycin in A549
388 and BEAS-2B cells, the intracellular BCG was significantly decreased (Fig 11A&11B
389 and S2J&S2K Fig). However, hBD1 or/and LL37 silencing during the autophagy
390 process weakened the autophagy function of killing the intracellular BCG (Fig 11B,
391 11C&11D and S2J, S2K&S2L Fig). These results indicated that hBD1 and LL37 play
392 an important role in autophagic killing of BCG in lung epithelial cells, identifying
393 autophagy-related AMP production as a novel mechanism of autophagy-mediated
394 MTB killing.

395

396 **Discussion**

397 During pathogen invasion, AMPs can directly inhibit microbial growth and regulate
398 inflammatory responses by attenuating damage and stimulating beneficial responses.
399 [18]. In this study, we screened AMPs hBD1 and LL37 as highly expressing in
400 PBMCs and alveolar epithelial cells in pathological sections of patients with TB.
401 Furthermore, we verified that the expression of active hBD1 and LL37 involves
402 autophagy, and that this process is related to AMP precursor cleavage with p62 also
403 being involved. Moreover, we demonstrated that AMPs produced by autophagy could
404 play an important role in the autophagic killing of intracellular BCG. These findings
405 open new avenues for further research regarding anti-TB immune mechanisms and
406 the potential for new TB treatment strategies.

407 To further understand the functional mechanisms of the hBD1 and LL37 in the
408 defense against MTB invasion by lung epithelial cells, we explored the expression
409 mechanism of hBD1 and LL37 in A549 and BEAS-2B cells. To confirm whether the
410 AMP production process, wherein an expressed precursor form is cleaved by a
411 proteolytic process to release the active peptide [18], is related to the occurrence of
412 autophagy, we conducted various interventions toward the autophagy level of A549
413 and BEAS-2B cells. The results showed that the active AMP expression level
414 positively correlates with the autophagy level, whereas modulating the autophagy
415 level does not affect AMP mRNA levels. Moreover, immunofluorescence assays
416 confirmed that the LL37 precursor hCAP18 entered the autophagosomes, revealing
417 that the co-localization rates between hCAP18 and autophagosomes were influenced
418 by the autophagy process in consonance with the active protein level of AMPs. These

419 findings highlighted that the autophagic level of lung epithelial cells could affect the
420 protein levels of hBD1 and LL37 active peptides and that this occurs in a
421 post-transcriptional manner, likely through the autophagic cleavage of antibacterial
422 peptide precursors. Although various previously identified AMP shearing
423 mechanisms have been found to occur during e.g., cell exocytosis [20] and
424 phagocytosis [32], our findings suggested that autophagy might constitute a
425 previously uncharacterized cleavage mechanism of AMPs. In particular, whereas it
426 was previously shown that the autophagic process can also cleave antibacterial
427 peptide precursors [30], this cleavage mechanism had not been validated in the
428 classical three antibacterial peptide families. Conversely, the mechanism described in
429 the present study was also confirmed as affecting hBD1 and LL37.

430 We next explored the role of lysosomes in the autophagic production of hBD1 and
431 LL37 as once the autophagosome encloses the targeted material and forms a closed
432 bilayer membrane structure, it fuses with a lysosome and undergoes acidification to
433 dissolve and degrade enveloped contents by forming autophagosomes [33,34]. We
434 used Baf A1 to inhibit autophagosome and lysosome fusion to interrupt the later
435 process of autophagy, and NH₄Cl to prevent the acidification as a lysosomal function
436 inhibitor, and observed whether this process affected hBD1 and LL37 production. Our
437 analysis showed that the active protein levels of hBD1 and LL37 were
438 down-regulated, regardless of autophagy induction by BCG or rapamycin. However,
439 neither Baf A1 nor NH₄Cl stimulation affected the mRNA levels of hBD1 and LL37.
440 Additionally, these inhibitors could not affect AMP precursor hCAP18 recruitment to

441 and entry into autolysosomes, as shown by immunofluorescence results. These results
442 suggested that lysosome function and autolysosome formation are critical to the
443 autophagy-related production of active hBD1 and LL37, but do not influence AMP
444 precursor recruitment.

445 To evaluate how the AMP precursors selectively enter the autophagosome, we
446 focused on the autophagic adaptor protein p62, which facilitates the function of
447 autophagy to clear protein aggregates. In neurodegenerative diseases, p62 can mediate
448 the transport of cytosolic proteins to lysosomes and effect their cytoplasmic
449 proteolysis into AMPs in macrophages [35]. Notably, this function appears to be
450 specific to p62, as other autophagic adaptor proteins, such as NBR1, do not exhibit
451 the ability to recruit MTB phagosomes in the autophagy process, although NBR1 in
452 particular shows similar function to p62 during its interaction with LC3 and
453 recruitment of ubiquitinated proteins [35–37]. Additional studies revealed that
454 lysosomal hydrolase function and the acidification of MTB-containing vesicles are
455 completely independent of p62 in autophagy up-regulated macrophages, whereas p62
456 plays a special role in autophagic antimicrobial activity [30].

457 Therefore, we interrogated whether p62 is involved in the production of hBD1 and
458 LL37 active peptides. Our results showed that silencing p62 in A549 cells
459 down-regulated hBD1 and LL37 active protein levels but did not affect their mRNA
460 levels. Moreover, co-localization was observed among p62, hCAP18,
461 autophagosomes, and lysosomes with p62 able to directly interact with hCAP18, as
462 shown by immunofluorescence and immunoprecipitation, respectively. These results

463 suggested that p62 is involved in active hBD1 and LL37 production, with the direct
464 interaction with hCAP18 indicating that p62 affects AMP expression by recruiting
465 antimicrobial peptide precursors to autophagosomes.

466 Autophagy can play a role in fighting MTB infection in the natural immune
467 process through a variety of mechanisms, such as facilitating the resolution of
468 intracellular MTB, producing functional cytokines and effector proteins, or regulating
469 inflammatory responses [38–40]. Based on the findings of the present study, we
470 hypothesized that autophagy produces active AMPs to exert its antibacterial function
471 against intracellular MTB. To verify this conjecture, we performed a colony
472 formation assay. Statistical analysis of the survival rate of BCG in A549 and
473 BEAS-2B cells showed that following rapamycin treatment, the intracellular BCG
474 survival rate decreased, whereas this effect was ameliorated upon concurrent silencing
475 of hBD1 and/or LL37. This phenomenon indicated that the AMP production plays a
476 crucial role in the process of anti-intracellular BCG infection in
477 autophagy-up-regulated lung epithelial cells, highlighting AMP production as an
478 important mechanism by which autophagy plays its role in killing MTB.

479 In summary, we observed the high expression of hBD1 and LL37 in PBMCs and
480 lung epithelial type II cells of patients with TB and in A549 and BEAS-2B cells
481 infected with BCG, and verified the involvement of autophagy and autolysosomes in
482 the production of active hBD1 and LL37, and of autophagic adaptor protein p62 in the
483 selective recruitment of AMP precursors. Our results suggested that classic AMP
484 precursors could be sheared during the autophagy process, thus producing active

485 AMPs to exhibit anti-MTB activity. These findings will enhance our understanding
486 regarding the antibacterial function of epithelial cells in the process of natural
487 immunity during MTB invasion, and provide a new perspective for designing new
488 treatments for TB.

489

490 **Funding**

491 This work was supported by National Science and Technology Major Project
492 (2017ZX10201301-008), National Natural Science Foundation of China (81772150),
493 Guangdong Natural Science Foundation (2017A030313832), Science and Technology
494 Project of Guangdong Province (2017A020212007), and Science and Technology
495 Project of Guangzhou (201707010215).

496

497 **Availability of data and materials**

498 The datasets used and/or analyzed during the current study are available from the
499 corresponding author on reasonable request.

500

501 **Ethics approval and consent to participate**

502 Prior to sample collection, written informed consents were obtained and the study
503 approved by the Ethics Committee of the Southern Medical University.

504

505 **Consent for publication**

506 All healthy volunteers provided informed consent and agreed to the publication of

507 relevant data and related images.

508

509 **Competing interests**

510 The authors declare no conflict of interest. The authors alone are responsible for the
511 content and writing of the paper.

512

513 **References**

- 514 1. World Health Organization. Global Tuberculosis Report 2019. TB Fact sheet
515 [Internet]. 2019;1–2. Available from:
516 <https://apps.who.int/iris/bitstream/handle/10665/329368/9789241565714-eng.pdf?ua=1>
- 517 2. Bermudez LE, Goodman J. *Mycobacterium tuberculosis* invades and replicates
518 within type II alveolar cells. *Infect. Immun.* 1996;64:1400–1406.
- 519 3. Fine KL, Metcalfe MG, White E, et al. Involvement of the autophagy pathway
520 in trafficking of *Mycobacterium tuberculosis* bacilli through cultured human
521 type II epithelial cells. *Cell. Microbiol.* 2012;14:1402–1414.
- 522 4. Mehta PK, King CH, White EH, et al. Comparison of in vitro models for the
523 study of *Mycobacterium tuberculosis* invasion and intracellular replication.
524 *Infect. Immun.* 1996;64:2673–2679.
- 525 5. Dobos KM, Spotts EA, Quinn FD, et al. Necrosis of lung epithelial cells during
526 infection with *Mycobacterium tuberculosis* is preceded by cell permeation.
527 *Infect. Immun.* 2000;68:6300–6310.

529 6. Bevins CL, Salzman NH. Paneth cells, antimicrobial peptides and maintenance
530 of intestinal homeostasis. *Nat. Rev. Microbiol.* 2011. p. 356–368.

531 7. Harder J, Meyer-Hoffert U, Teran LM, et al. Mucoid *Pseudomonas aeruginosa*,
532 TNF-alpha, and IL-1beta, but not IL-6, induce human beta-defensin-2 in
533 respiratory epithelia. *Am. J. Respir. Cell Mol. Biol.* 2000;22:714–721.

534 8. Mendez-Samperio P, Miranda E, Trejo A. *Mycobacterium bovis* Bacillus
535 Calmette-Guerin (BCG) stimulates human beta-defensin-2 gene transcription in
536 human epithelial cells. *Cell Immunol* [Internet]. 2006;239:61–66. Available
537 from:
538 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16762333.

540 9. Yang X, Cheng YT, Tan MF, et al. Overexpression of porcine beta-defensin 2
541 enhances resistance to *Actinobacillus pleuropneumoniae* infection in pigs.
542 *Infect. Immun.* 2015;83:2836–2843.

543 10. Jarczak J, Kościuczuk EM, Lisowski P, et al. Defensins: Natural component of
544 human innate immunity. *Hum. Immunol.* 2013. p. 1069–1079.

545 11. Castaneda-Sanchez JI, Garcia-Perez BE, Munoz-Duarte a R, et al. Defensin
546 production by human limbo-corneal fibroblasts infected with mycobacteria.
547 *Pathogens* [Internet]. 2013;2:13–32. Available from:
548 <http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L372464405%5Cnhttp://dx.doi.org/10.3390/pathogens2010013>.

550 12. García-Pérez BE, Villagómez-Palatto DA, Castañeda-Sánchez JI, et al. Innate

551 response of human endothelial cells infected with mycobacteria.

552 Immunobiology. 2011;216:925–935.

553 13. Ganz T. Antimicrobial polypeptides in host defense of the respiratory tract. *J. Clin. Invest.* 2002. p. 693–697.

555 14. Schutte BC, McCray PB. [Beta]-Defensins in Lung Host Defense. *Annu. Rev. Physiol.* [Internet]. 2002;64:709–748. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/11826286>.

557 15. Ganz T. Defensins: Antimicrobial peptides of innate immunity. *Nat. Rev. Immunol.* 2003. p. 710–720.

560 16. Tecle T, Tripathi S, Hartshorn KL. Defensins and cathelicidins in lung immunity. *Innate Immun.* 2010. p. 151–159

562 17. Martineau AR, Newton SM, Wilkinson KA, et al. Neutrophil-mediated innate 563 immune resistance to mycobacteria. *J. Clin. Invest.* 2007;117:1988–1994.

564 18. Lai Y, Gallo RL. AMPed up immunity: how antimicrobial peptides have 565 multiple roles in immune defense. *Trends Immunol.* 2009. p. 131–141.

566 19. Castaneda-Sanchez JI, Garcia-Perez BE, Munoz-Duarte a R, et al. Defensin 567 production by human limbo-corneal fibroblasts infected with mycobacteria. 568 *Pathogens* [Internet]. 2013;2:13–32. Available from: <http://www.embase.com/search/results?subaction=viewrecord&from=export&i>

569 d=L372464405%5Cn<http://dx.doi.org/10.3390/pathogens2010013>.

571 20. Sørensen OE, Follin P, Johnsen AH, et al. Human cathelicidin, hCAP-18, is 572 processed to the antimicrobial peptide LL-37 by extracellular cleavage with

573 proteinase 3. *Blood*. 2001;97:3951–3959.

574 21. Valore E V, Ganz T. Posttranslational processing of defensins in immature
575 human myeloid cells. *Blood* [Internet]. 1992;79:1538–1544. Available from:
576 <http://www.ncbi.nlm.nih.gov/pubmed/1339298>.

577 22. Yount NY, Wang MS, Yuan J, et al. Rat neutrophil defensins. Precursor
578 structures and expression during neutrophilic myelopoiesis. *J. Immunol.*
579 1995;155:4476–4484.

580 23. Rice W, Ganz T, Kinkade J, et al. Defensin-rich dense granules of human
581 neutrophils. *Blood*. 1987;70:757–765.

582 24. Di Nardo A, Vitiello A, Gallo RL. Cutting Edge: Mast Cell Antimicrobial
583 Activity Is Mediated by Expression of Cathelicidin Antimicrobial Peptide. *J.*
584 *Immunol.* [Internet]. 2003;170:2274–2278. Available from:
585 <http://www.jimmunol.org/cgi/doi/10.4049/jimmunol.170.5.2274>.

586 25. Nell MJ, Sandra Tjabringa G, Vonk MJ, et al. Bacterial products increase
587 expression of the human cathelicidin hCAP-18/LL-37 in cultured human sinus
588 epithelial cells. *FEMS Immunol. Med. Microbiol.* 2004;42:225–231.

589 26. Gutierrez MG, Master SS, Singh SB, et al. Autophagy is a defense mechanism
590 inhibiting BCG and Mycobacterium tuberculosis survival in infected
591 macrophages. *Cell*. 2004;119:753–766.

592 27. Ponpuak M, Davis AS, Roberts EA, et al. Delivery of Cytosolic Components
593 by Autophagic Adaptor Protein p62 Endows Autophagosomes with Unique
594 Antimicrobial Properties. *Immunity*. 2010;32:329–341.

595 28. Singh SB, Davis AS, Taylor GA, et al. Human IRGM induces autophagy to
596 eliminate intracellular mycobacteria. *Science* (80-.). 2006;313:1438–1441.

597 29. Jo EK. Autophagy as an innate defense against mycobacteria. *Pathog. Dis.*
598 2013. p. 108–118.

599 30. Davis AS, Roberts EA, et al. Delivery of Cytosolic Components by Autophagic
600 Adaptor Protein p62 Endows Autophagosomes with Unique Antimicrobial
601 Properties. *Immunity*. 2010;32:329–341.

602 31. Alonso S, Pethe K, Russell DG, et al. Lysosomal killing of *Mycobacterium*
603 mediated by ubiquitin-derived peptides is enhanced by autophagy. *Proc. Natl.*
604 *Acad. Sci. [Internet]*. 2007;104:6031–6036. Available from:
605 <http://www.pnas.org/cgi/doi/10.1073/pnas.0700036104>.

606 32. c, Yamasaki K, Kabigting FD, et al. Kallikrein expression and cathelicidin
607 processing are independently controlled in keratinocytes by calcium, vitamin D
608 3, and retinoic acid. *J. Invest. Dermatol.* 2010;130:1297–1306.

609 33. Mizushima N, Levine B, Cuervo AM, et al. Autophagy fights disease through
610 cellular self-digestion. *Nature*. 2008. p. 1069–1075.

611 34. Xie Z, Klionsky DJ. Autophagosome formation: Core machinery and
612 adaptations. *Nat. Cell Biol.* 2007. p. 1102–1109.

613 35. Bjørkøy G, Lamark T, Brech A, et al. p62/SQSTM1 forms protein aggregates
614 degraded by autophagy and has a protective effect on huntingtin-induced cell
615 death. *J. Cell Biol.* 2005;171:603–614.

616 36. Pankiv S, Clausen TH, Lamark T, et al. p62/SQSTM1 binds directly to

617 Atg8/LC3 to facilitate degradation of ubiquitinated protein aggregates by
618 autophagy*[S]. *J. Biol. Chem.* 2007;282:24131–24145.

619 37. Kirkin V, Lamark T, Sou YS, et al. A Role for NBR1 in Autophagosomal
620 Degradation of Ubiquitinated Substrates. *Mol. Cell.* 2009;33:505–516.

621 38. Klionsky DJ, Emr SD. Autophagy as a regulated pathway of cellular
622 degradation. *Science* (80-.). 2000. p. 1717–1721.

623 39. Sultana Rekha R, Rao Muvva SJ, Wan M, et al. Phenylbutyrate induces
624 LL-37-dependent autophagy and intracellular killing of mycobacterium
625 tuberculosis in human macrophages. *Autophagy*. 2015;11:1688–1699.

626 40. Shin DM, Yuk JM, Lee HM, et al. Mycobacterial lipoprotein activates
627 autophagy via TLR2/1/CD14 and a functional vitamin D receptor signalling.
628 *Cell. Microbiol.* 2010;12:1648–1665.

629

630 **Supporting information**

631 **Figure 1. Antimicrobial peptides hBD1 and LL37 are highly expressed in**
632 **MTB-infected lung epithelial cells and exhibit anti-MTB activity.**

633 (A) High level expression of hBD1 and LL37 was detected in A549 cells. The cells
634 were infected with BCG for 48 h and the seven AMP mRNAs were evaluated by
635 real-time PCR. (B&C) *hBD1* (B) and *LL37* (C) mRNA expression in BCG-infected
636 A549 cells was detected at specified time points by real-time PCR. (D) The active
637 peptides of hBD1 and LL37 were detected at specified time points and evaluated by
638 western blotting. (E&F) High level expression of *hBD1* and *LL37* mRNA in PBMCs

639 of patients with TB. (G) High level expression of LL37 was detected in human
640 alveolar type II pneumocytes from patients with TB via immunohistochemistry.
641 Micrograph shows strong LL37 immunostaining in human alveolar type II
642 pneumocytes from patients with TB compared to that in healthy tissue donors and
643 patients with pneumoconiosis (magnification x200). (H-J) Silencing of hBD1 or/and
644 LL37 decreased intracellular BCG killing in A549 cells. The intracellular viable
645 bacilli were determined by CFU assays at 72 h. Survival rate was calculated compared
646 with that at 0 h. Data are expressed as the means \pm standard deviation (s.d.). * $p < 0.05$,
647 *** $p < 0.001$, **** $p < 0.0001$. These experiments were performed independently at
648 least thrice with similar results.

649

650 **Figure 2. Autophagy influences the active peptide levels of hBD1 and LL37.**

651 (A) The autophagic level of A549 cells affected the active peptides level of hBD1 and
652 LL37. A549 cells were pretreated with 4 μ M rapamycin for 6 h and 5 mM 3-MA for 2
653 h and then infected with BCG for 24 h. The active peptide levels of hBD1 and LL37
654 were evaluated by western blotting. (B) The autophagic level of A549 cells did not
655 affect the mRNA level of hBD1 and LL37. A549 cells were pretreated and infected
656 with BCG as described above. The mRNA levels of hBD1 and LL37 were evaluated
657 using real-time PCR. (C&D) Starvation-induced autophagy promoted the production
658 of active hBD1 and LL37. A549 cells were cultured with EBSS culture medium at
659 various time points. The expression of hBD1 and LL37 was detected by western
660 blotting and real-time PCR. (E&F) Silencing ATG 5 and 7 disturbed the production of

661 active hBD1 and LL37. A549 cells were transfected with 100 nM si-control or siRNA
662 for ATG 5 and 7 for 72 h and infected with BCG. The expression of hBD1 and LL37
663 was detected by western blotting and real-time PCR. (G) The autophagic level of
664 A549 cells affected the co-localization level of hBD1/LL37 precursor and
665 autophagosomes. A549 cells stably expressing green fluorescent protein (GFP)-
666 tagged LC3 (GFP-LC3) and mCherry Fluorescence Protein (mCherry)-tagged hBD1
667 or LL37 precursor (hBD1/LL37 precursor-mCherry) were pretreated with rapamycin
668 and 3-MA and infected with BCG as described above. GFP-LC3 puncta ($>1 \mu\text{m}$) were
669 observed and counted under confocal microscopy. Co-localization of hBD1/LL37
670 precursor and autophagosomes was detected by confocal microscopy. Data are
671 expressed as the means \pm standard deviation (s.d.) * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$,
672 **** $p < 0.0001$. These experiments were performed independently at least thrice with
673 similar results.

674

675 **Figure 3. The autophagic level of A549 cells affected the co-localization level of**
676 **hBD1 precursor and autophagosomes.**

677 A549 cells stably expressing green fluorescent protein (GFP)-tagged LC3 (GFP-LC3)
678 and mCherry Fluorescence Protein (mCherry)-tagged hBD1 precursor (hBD1
679 precursor-mCherry) were pretreated with rapamycin and 3-MA as described above
680 and infected with BCG as described above. GFP-LC3 puncta ($>1 \mu\text{m}$) were observed
681 and counted under confocal microscopy. Co-localization of hBD1 precursor and
682 autophagosomes was detected by confocal microscopy. These experiments were

683 performed independently at least thrice with similar results.

684

685 **Figure 4. The autophagic level of A549 cells affected the co-localization level of**
686 **LL37 precursor and autophagosomes.**

687 A549 cells stably expressing green fluorescent protein (GFP)-tagged LC3 (GFP-LC3)
688 and mCherry Fluorescence Protein (mCherry)-tagged LL37 precursor (LL37
689 precursor-mCherry) were pretreated with rapamycin and 3-MA as described above
690 and infected with BCG as described above. GFP-LC3 puncta ($>1 \mu\text{m}$) were observed
691 and counted under confocal microscopy. Co-localization of LL37 precursor and
692 autophagosomes was detected by confocal microscopy. These experiments were
693 performed independently at least thrice with similar results.

694

695 **Figure 5. hBD1 and LL37 production was affected by the function of lysosomes.**

696 (A) The formation of autolysosomes affected the active peptide levels of hBD1 and
697 LL37. A549 cells were pretreated with 0.1 mM Baf A1 or/and 4 μM rapamycin and
698 infected with BCG for 48 h. The active peptide levels of hBD1 and LL37 were
699 evaluated using western blotting. (B) The formation of autolysosomes did not affect
700 the mRNA level of hBD1 and LL37. A549 cells were pretreated and infected with
701 BCG as described above. The mRNA levels of hBD1 and LL37 were evaluated using
702 real-time PCR. (C) The function of lysosomes affected the active peptide levels of
703 hBD1 and LL37. A549 cells were pretreated with 10 mg/mL NH4Cl and infected with
704 BCG for 48 h. The active peptide levels of hBD1 and LL37 were evaluated by

705 western blotting. (D) The function of lysosomes did not affect the mRNA level of
706 hBD1 and LL37. A549 cells were pretreated and infected with BCG as described
707 above. The mRNA levels of hBD1 and LL37 were evaluated using real-time PCR.
708 (E&F) The formation of autolysosomes did not affect the co-localization rates
709 between hBD1/LL37 precursor and autolysosomes. A549 cells stably expressing
710 GFP-tagged LC3 (GFP-LC3) and mCherry Fluorescence Protein (mCherry)-tagged
711 hBD1 or LL37 precursor (hBD1/LL37 precursor-mCherry) were pretreated and
712 infected with BCG as described as (A). Lysosome was labelled with lyso tracker,
713 GFP-LC3 ($>1 \mu\text{m}$) and lyso tracker double positive puncta were determined as
714 autolysosomes. Co-localization of hBD1/LL37 precursor and autolysosomes was
715 detected by confocal microscopy. Data are expressed as the means \pm standard
716 deviation (s.d.) $*p < 0.05$, $****p < 0.0001$. These experiments were performed
717 independently at least thrice with similar results.

718

719 **Figure 6. The formation of autolysosomes could not affect the co-localization**
720 **rates between hBD1 precursor and autolysosomes.**

721 A549 cells stably expressing GFP-tagged LC3 (GFP-LC3) and mCherry
722 Fluorescence Protein (mCherry)-tagged hBD1 precursor (hBD1 precursor-mCherry)
723 were pretreated with 0.1 mM Baf A1 or/and 4 μM rapamycin and infected with BCG
724 for 48 h. Lysosome was labelled with lyso tracker, GFP-LC3 ($>1 \mu\text{m}$) and lyso
725 tracker double positive puncta were determined as autolysosomes. The function of
726 lysosomes could not affect the co-localization rates between hBD1 precursor and

727 autolysosomes. These experiments were performed independently at least thrice with
728 similar results.

729

730 **Figure 7. The formation of autolysosomes could not affect the co-localization**
731 **rates between LL37 precursor and autolysosomes.**

732 A549 cells stably expressing GFP-tagged LC3 (GFP-LC3) and mCherry
733 Fluorescence Protein (mCherry)-tagged LL37 precursor (LL37 precursor-mCherry)
734 were pretreated with 0.1 mM Baf A1 or/and 4 μ M rapamycin and infected with BCG
735 for 48 h. Lysosome was labelled with lyso tracker, GFP-LC3 ($>1 \mu$ m) and lyso
736 tracker double positive puncta were determined as autolysosomes. The function of
737 lysosomes could not affect the co-localization rates between LL37 precursor and
738 autolysosomes. These experiments were performed independently at least thrice with
739 similar results.

740

741 **Figure 8. Autophagy adapter protein p62 controls the production of active AMPs**
742 **by interacting with AMP precursors.**

743 (A&B) Silencing P62 affected the active peptide levels of hBD1 and LL37. A549
744 cells were transiently transfected with si-control or si-SQSTM1 to silence P62 and
745 then infected with BCG. The expression of hBD1 and LL37 was detected using
746 western blotting and real-time PCR. (C) The autophagic level of A549 cells affected
747 the co-localization level of hBD1/LL37 precursor and p62-positive autophagosomes.
748 A549 cells stably expressing green fluorescent protein (GFP)-tagged LC3 (GFP-LC3)

749 and mCherry Fluorescence Protein (mCherry)-tagged LL37 precursor (LL37
750 precursor-mCherry) were pretreated with 3-MA and rapamycin and infected with
751 BCG as described above. GFP-LC3 puncta ($>1 \mu\text{m}$) were observed and counted under
752 confocal microscopy. Co-localization of hBD1/LL37 precursor, p62, and GFP-LC3,
753 labeled using Alexa Fluor 647-coupled antibody against p62, was detected by
754 confocal microscopy. (D) Direct interaction could be observed between p62 and
755 hCAP18. A549 cells were infected with BCG for 24 and 48 h. The interaction
756 between p62 and hCAP18 was detected by Co-IP with anti-p62 antibody followed by
757 western blotting with anti-p62 and anti-hCAP18 antibodies. Data are expressed as the
758 means \pm standard deviation (s.d.) $*p < 0.05$, $***p < 0.001$, $****p < 0.0001$. These
759 experiments were performed independently at least thrice with similar results.
760

761 **Figure 9. The autophagic level of A549 cells affected the co-localization level of**
762 **hBD1 precursor and p62 positive autophagosomes.**

763 A549 cells stably expressing green fluorescent protein (GFP)-tagged LC3 (GFP-LC3)
764 and mCherry Fluorescence Protein (mCherry)-tagged hBD1 precursor (hBD1
765 precursor-mCherry) were pretreated with 3-MA and Rapamycin and infected with
766 BCG as described above. GFP-LC3 puncta ($>1 \mu\text{m}$) were observed and counted
767 under confocal microscopy. Co-localization of hBD1, p62 and GFP-LC3, marked
768 with Alexa Fluor 647-coupled antibody against p62, was detected by confocal
769 microscopy. These experiments were performed independently at least thrice with
770 similar results.

771

772 **Figure 10. The autophagic level of A549 cells affected the co-localization level of**
773 **LL37 precursor and p62 positive autophagosomes.**

774 A549 cells stably expressing green fluorescent protein (GFP)-tagged LC3 (GFP-LC3)
775 and mCherry Fluorescence Protein (mCherry)-tagged LL37 precursor (LL37
776 precursor-mCherry) were pretreated with 3-MA and Rapamycin and infected with
777 BCG as described above. GFP-LC3 puncta ($>1 \mu\text{m}$) were observed and counted
778 under confocal microscopy. Co-localization of LL37, p62 and GFP-LC3, marked
779 with Alexa Fluor 647-coupled antibody against p62, was detected by confocal
780 microscopy. These experiments were performed independently at least thrice with
781 similar results.

782

783

784 **Figure 11. Autophagy-related production of antimicrobial peptides is a novel**
785 **mechanism of autophagy-mediated BCG killing.**

786 (A-C) Silencing of hBD1 (A) or/and LL37 (B&C) weakened the autophagic killing of
787 intracellular BCG. A549 cells were transfected with si-NC, Si-DEFB1, or/and
788 si-CAMP for 24 h then infected with BCG (MOI = 5) for 1 h. In the rapamycin
789 (Rapa) group the cells were pretreated by 4 μM rapamycin for 6 h prior to BCG
790 infection. The intracellular viable bacilli were determined by CFU assays at 72 h.
791 Survival rate was calculated compared with that at 0 h. Data are expressed as the
792 means \pm standard deviation (s.d.) * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$.

793 These experiments were performed independently at least thrice with similar results.

794

795 **Supplementary Figure S1. Electron microscopy analysis of BCG-infected lung**
796 **epithelial cells.**

797 A549 and BEAS-2B cells were infected with BCG for 1 h (MOI = 5). The bacilli
798 were observed inside cells (red arrow) and enveloped by the bilayer membrane
799 autophagosomes (yellow arrow).

800

801 **Supplementary Figure S2. Antimicrobial peptides hBD1 and LL37 were highly**
802 **expressed in BCG-infected lung epithelial cells and exhibit anti-MTB activity.**

803 (A) The active peptides of hBD1 and LL37 were detected at indicated time points and
804 evaluated by western blotting. (B, C) *hBD1* (b) and *LL37* (C) mRNA expression in
805 BCG-infected BEAS-2B cells was detected at indicated time points using real-time
806 PCR. (D) The autophagic level of BEAS-2B cells affected the active peptide levels of
807 hBD1 and LL37. BEAS-2B cells were pretreated with 4 μ M rapamycin for 6 h and 5
808 mM 3-MA for 2 h and then infected with BCG for 24 h. The active peptide levels of
809 hBD1 and LL37 were evaluated using western blotting. (E, F) The autophagic level of
810 BEAS-2B cells did not affect the mRNA level of hBD1 (E) and LL37 (F). BEAS-2B
811 cells were pretreated and infected with BCG as described above. The mRNA levels of
812 hBD1 and LL37 were evaluated using real-time PCR. (G-I) Silencing of hBD1 or/and
813 LL37 decreased intracellular BCG killing in BEAS-2B cells. The intracellular viable
814 bacilli were determined using a CFU assay at 72 h. The survival rate of BCG was

815 calculated in comparison with that at 0 h. (J-L) Silencing of hBD1 or/and LL37
816 weakened the autophagic killing of intracellular BCG. BEAS-2B cells were
817 transfected with si-NC, si-DEFB1, or/and si-CAMP for 24 h, then infected with BCG
818 (MOI = 5) for 1 h. In the rapamycin (Rapa) group, the cells were pretreated with 4
819 μ M rapamycin for 6 h prior to BCG infection. The intracellular viable bacilli were
820 determined using CFU assays at 72 h. Survival rate was calculated compared with that
821 at 0 h. Data are expressed as the means \pm standard deviation (s.d.). * p < 0.05, ** p <
822 *** p < 0.001, **** p < 0.0001. These experiments were performed
823 independently at least thrice with similar results.

824

825 **Supplementary Figure S3. LL37 expression level in various TB lesions.**

826 (A) High level expression of LL37 was detected in human alveolar type II
827 pneumocytes from patients with TB via immunohistochemistry. Micrograph shows
828 strong LL37 immunostaining in human alveolar type II pneumocytes from patients
829 with TB compared to that in granuloma, caseous necrosis, and immune cells
830 (magnification \times 200). (B) Average optical of immunohistochemistry photographs
831 from (A). Data are expressed as the means \pm standard deviation (s.d.). **** p <
832 0.0001. These experiments were performed independently at least thrice with similar
833 results.

834

835 **Supplementary Figure S4. AMP expression levels in various cell types.**

836 A549, BEAS-2B, THP1, and HMDMs were infected with BCG for 48 h and the

837 hBD1 and LL37 mRNA were detected using qPCR. Data are expressed as the means
838 \pm standard deviation (s.d.). * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$. These experiments
839 were performed independently at least thrice with similar results.

840

841





Figure 1

A

bioRxiv preprint doi: <https://doi.org/10.1101/2020.02.21.959361>; this version posted February 21, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.







B**D****F****C****E****G**




Figure 2

hBD1 precursor




LC3

Merge




BCG- DMSO






BCG- 3-MA






BCG- Rapa



BCG+ DMSO



BCG+ 3-MA



BCG+ Rapa






Figure 3

bioRxiv preprint doi: <https://doi.org/10.1101/2020.02.21.959361>; this version posted February 21, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](#).




Figure 4




Figure 5




Figure 6




Figure 7







Figure 8




Figure 9







Figure 10

A**B****C****Figure 11**